Iron deficiency: What are the future trends in diagnostics and therapeutics?

Clinical Chemistry

Volumn 59, Issue 5, 2013, Pages 740-745

  Brugnara, Carlo ^a   Adamson, John ^b   Auerbach, Michael ^c   Kane, Robert ^d   Macdougall, Iain ^e   Mast, Alan ^f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRITIN; FERROUS GLUCONATE; HEPCIDIN; IRON; IRON DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; BLEEDING; CHRONIC KIDNEY DISEASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG SURVEILLANCE PROGRAM; ENTERITIS; ERYTHROCYTE; ERYTHROPOIESIS; FUTUROLOGY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; NOTE; RETICULOCYTE HEMOGLOBIN CONTENT; SUBSTITUTION THERAPY; TREATMENT PLANNING; TREND STUDY;

ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; DELIVERY OF HEALTH CARE; FORECASTING; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84876924668     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.182071     Document Type: Note

References (0)